Laquinimod Explained

Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.

Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide.[1]

The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI.[2] [3] [4] However, the response to a given dose was discrepant between both studies.[5]

Phase III studies for MS started in December 2007. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses in MS among patients beyond a placebo.[6] However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.[7]

On May 7, 2013 laquinimod was approved by the Russian Ministry of Health (the FDA analog) as a treatment for relapsing-remitting multiple sclerosis (RRMS) under the brand name Nerventra.[8]

See also

External links

Notes and References

  1. Tan IL . Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials . Mult Scler . 6 . 2 . 99–104 . April 2000 . 10773855 . vanc. Lycklama à Nijeholt GJ . Polman CH . 3 . Adèr . HJ . Herman J. Adèr . Barkhof . F . 10.1191/135245800678827626.
  2. Comi G . Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study . Lancet . 371 . 9630 . 2085–2092 . June 2008 . 18572078 . 10.1016/S0140-6736(08)60918-6 . vanc. Pulizzi A . Rovaris M . 3 . Abramsky . O . Arbizu . T . Boiko . A . Gold . R . Havrdova . E . Komoly . S.
  3. Polman C . Treatment with laquinimod reduces development of active MRI lesions in relapsing MS . Neurology . 64 . 6 . 987–91 . March 2005 . 15781813 . 10.1212/01.WNL.0000154520.48391.69 . vanc. Barkhof F . Sandberg-Wollheim M . 3 . Linde . A . Nordle . O . Nederman . T . Laquinimod in Relapsing MS Study Group.
  4. He. Dian. Han. Kai. Gao. Xiangdong. Dong. Shuai. Chu. Lan. Feng. ZhanHui. Wu. Shan. Lan. Chu. 2013-08-06. Laquinimod for multiple sclerosis. The Cochrane Database of Systematic Reviews. 8. CD010475. 10.1002/14651858.CD010475.pub2. 1469-493X. 23922214.
  5. Keegan BM, Weinshenker BG . Laquinimod, a new oral drug for multiple sclerosis . Lancet . 371 . 9630 . 2059–2060 . June 2008 . 18572062 . 10.1016/S0140-6736(08)60894-6.
  6. News: Kresege. Naomi. Teva's Copaxone Successor Fails in Latest Clinical Trial. 2 August 2011. Bloomberg. 1 August 2011. Teva Pharmaceutical Industries Ltd. (TEVA)’s experimental multiple sclerosis pill failed to reduce relapses more than placebo in a clinical trial, dealing a blow to the company’s effort to find a successor to an older drug..
  7. Comi . G. . Jeffery . D. . Kappos . L. . Montalban . X. . Boyko . A. . Rocca . M. A. . Filippi . M. . Allegro Study . G. . Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis . 10.1056/NEJMoa1104318 . New England Journal of Medicine . 366 . 11 . 1000–1009 . 2012 . 22417253. 10459.1/65687 . free .
  8. Web site: Nerventra (laquinimod) Capsules 0,6 mg. Registration certificate. State Register of Medicines. 21 October 2015. ru.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Laquinimod".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.